PDF herunterladen
CC BY-NC-ND 4.0 · Int Arch Otorhinolaryngol 2020; 24(03): e351-e358
DOI: 10.1055/s-0040-1714143
Update Article
Special Article COVID-19
Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil

The COVID-19 Pandemic and Planetary Health. A Critical Review of Epidemiology, Prevention, Clinical Characteristics and Treatments for Oral, Head and Neck Health Professionals. Do We Have a Roadmap?

Geraldo Pereira Jotz 
1   Department of Morphological Sciences, Institute of Basic Health Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
2   Health Sciences Post Graduate Program, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil
,
Airton Stein
3   Public Health Department, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil
4   Hospital Nossa Senhora da Conceição, Porto Alegre, RS, Brazil
,
Sérgio Sirena
4   Hospital Nossa Senhora da Conceição, Porto Alegre, RS, Brazil
5   School of Medicine, Universidade de Caxias do Sul, Caxias do Sul, RS, Brazil
,
Enrique Barros
5   School of Medicine, Universidade de Caxias do Sul, Caxias do Sul, RS, Brazil
,
Julio Baldisserotto
6   School of Dentistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
,
José Antônio Poli de Figueiredo
1   Department of Morphological Sciences, Institute of Basic Health Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
6   School of Dentistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
,
Joel Lavinsky 
1   Department of Morphological Sciences, Institute of Basic Health Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
,
Liviu Steier
7   University of Pennsylvania Health System, Philadelphia, PA, United States of America
,
Carlos Dora
8   School of Public Health, Columbia University, Columbia, NY, United States of America
9   Department of Public Health and the Environment at the World Health Organization, Geneva, Switzerland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

04. Juni 2020

11. Juni 2020

Publikationsdatum:
31. Juli 2020 (online)

   Lizenzen und Reprints

Abstract

Introduction Coronavirus disease 19 (COVID-19) is potentially the greatest global public health crisis of this century. This disease emerged as an outbreak of pneumonia of unknown cause in Wuhan, the capital city of the Hubei province in China, in December 2019. Otolaryngologists, head and neck surgeons and dentists are at an increased risk of occupational disease.

Objective The present review summarizes currently published evidence of Covid-19 epidemiology, clinical characteristics, treatment and prevention. No proven effective treatments for this disease currently exist.

Data Synthesis COVID-19 started from a zoonotic transmission event associated with a large seafood market that also traded in live wild animals, and it soon became clear that efficient person-to-person transmission was also occurring. Symptoms are varied, and not all patients develop all of them.

Conclusion Social distancing seems to have been successful in several places in the world. However, this recommendation alone is not enough to contain the disease, and it is not a long-term solution. Large-scale testing by health professionals of representative samples of the population may give an estimate of the progression of the disease. Different treatments are under test and bring hope of a cure to the population. However, no current treatments (April 27, 2020) have been proven to be the key to success in the treatment of patients with COVID-19. Planetary health is a useful concept to understand the current drivers of this pandemic and to draw a roadmap for science and healthcare that may guide actions to fight economic depression and ensure a healthy recovery.

Keywords

COVID-19 - planetary health - epidemiology - prevention - clinical characteristics - treatment
 

  • References

  • 1 Li Q, Guan X, Wu P. , et al. Early transmisión dynamics in Wuhan, China, of novel corona virus infected pneumonia. N Engl J Med 2020; 382 (13) 1199-1207 Doi: 10.1056/NEJMoa2001316
    CrossrefPubMedGoogle Scholar
  • 2 Huang C, Wang Y, Li X. , et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506 Doi: 10.1016/S0140-6736(20)30183-5
    CrossrefPubMedGoogle Scholar
  • 3 Kupferschmidt K. . Ending coronavirus lockdowns will be a dangerous process of trial and error. Science [Internet]. 2020 Apr 14 [cited 2020 June 03]. Doi: 10.1126/science.abc2507. Available from: https://www.sciencemag.org/news/2020/04/ending-coronavirus-lockdowns-will-be-dangerous-process-trial-and-error
    PubMed
  • 4 Coronavirus disease (COVID-19) pandemic. World Health Organization (WHO) [Internet]. [cited 2020 June 03]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
  • 5 McMichael TM, Currie DW, Clark S. , et al; Public Health–Seattle and King County, EvergreenHealth, and CDC COVID-19 Investigation Team. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington. N Engl J Med 2020; 382 (21) 2005-2011 Doi: 10.1056/NEJMoa2005412
    CrossrefPubMedGoogle Scholar
  • 6 The Lancet. COVID-19: protecting health-care workers. Lancet 2020; 395 (10228): 922 Doi: 10.1016/S0140-6736(20)30644-9
    CrossrefPubMedGoogle Scholar
  • 7 Xu J, Li Y, Gan F, Du Y, Yao Y. Salivary Glands: Potential Reservoirs for COVID-19 Asymptomatic Infection. J Dent Res 2020; 22034520918518: 22034520918518 Doi: 10.1177/0022034520918518
    Google Scholar
  • 8 van Doremalen N, Bushmaker T, Morris DH. , et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020; 382 (16) 1564-1567 Doi: 10.1056/NEJMc2004973
    CrossrefPubMedGoogle Scholar
  • 9 Harrel SK, Molinari J. Aerosols and splatter in dentistry: a brief review of the literature and infection control implications. J Am Dent Assoc 2004; 135 (04) 429-437 Doi: 10.14219/jada.archive.2004.0207
    CrossrefPubMedGoogle Scholar
  • 10 Topf MC, Shenson JA, Holsinger FC. , et al. Framework for prioritizing head and neck surgery during the COVID-19 pandemic. Head Neck 2020; 42 (06) 1159-1167 Doi: 10.22541/au.158594435.52569481
    CrossrefPubMedGoogle Scholar
  • 11 Kowalski LP, Sanabria A, Ridge JA. , et al. COVID-19 pandemic: Effects and evidence-based recommendations for otolaryngology and head and neck surgery practice. Head Neck 2020; 42 (06) 1259-1267 Doi: 10.22541/au.158567937.740924
    CrossrefPubMedGoogle Scholar
  • 12 Prasad A, Carey RM, Rajasekaran K. Head and neck virtual medicine in a pandemic era: Lessons from COVID-19. Head Neck 2020; 42 (06) 1308-1309 Doi: 10.22541/au.158594434.45036618
    CrossrefPubMedGoogle Scholar
  • 13 Lurie N, Carr BG. The Role of Telehealth in the Medical Response to Disasters. JAMA Intern Med 2018; 178 (06) 745-746 Doi: 10.1001/jamainternmed.2018.1314
    CrossrefPubMedGoogle Scholar
  • 14 Radonovich Jr LJ, Simberkoff MS, Bessesen MT. , et al; ResPECT investigators. N95 Respirators vs Medical Masks for Preventing Influenza Among Health Care Personnel: A Randomized Clinical Trial. JAMA 2019; 322 (09) 824-833 Doi: 10.1001/jama.2019.11645
    CrossrefPubMedGoogle Scholar
  • 15 Izzetti R, Nisi M, Gabriele M, Graziani F. COVID-19 Transmission in Dental Practice: Brief Review of Preventive Measures in Italy. J Dent Res 2020; 22034520920580: 22034520920580 Doi: 10.1177/0022034520920580 Online ahead of print.
    Google Scholar
  • 16 Odeh ND, Babkair H, Abu-Hammad S, Borzangy S, Abu-Hammad A, Abu-Hammad O. COVID-19: Present and Future Challenges for Dental Practice. Int J Environ Res Public Health 2020; 17 (09) E3151 Doi: 10.3390/ijerph17093151
    CrossrefPubMedGoogle Scholar
  • 17 Centers for Disease Control and Prevention – CDC - Coronavirus Disease. 2019 (COVID-19) Guidance for Dental Setting. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/dental-settings.html 1/10.
    PubMed
  • 18 Caruso AA, Del Prete A, Lazzarino AI. Hydrogen peroxide and viral infections: A literature review with research hypothesis definition in relation to the current covid-19 pandemic. Med Hypotheses 2020; 144: 109910
    CrossrefPubMedGoogle Scholar
  • 19 Wang D, Hu B, Hu C. , et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323 (11) 1061-1069 Doi: 10.1001/jama.2020.1585
    CrossrefPubMedGoogle Scholar
  • 20 Chen N, Zhou M, Dong X. , et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395 (10223): 507-513 Doi: 10.1016/S0140-6736(20)30211-7
    CrossrefPubMedGoogle Scholar
  • 21 Holshue ML, DeBolt C, Lindquist S. , et al; Washington State 2019-nCoV Case Investigation Team. Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382 (10) 929-936 Doi: 10.1056/NEJMoa2001191
    CrossrefPubMedGoogle Scholar
  • 22 Bann DV, Patel VA, Saadi R. , et al. Impact of coronavirus (COVID-19) on otolaryngologic surgery: Brief commentary. Head Neck 2020; 42 (06) 1227-1234 Doi: 10.22541/au.158567936.61156499
    CrossrefPubMedGoogle Scholar
  • 23 Mao L, Wang M, Chen S. , et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. medRxiv . Epub ahead of print 25 February 2020. Doi: 10.1101/2020.02.22.20026500
    Google Scholar
  • 24 Hopkins C, Kumar N. . Loss of sense of smell as marker of COVID-19 infection [Internet]. The Royal College of Surgeons of England, Published Online, 2020, Mar 22 [cited 2020 Mar 24]. Available from: https://www.entuk.org/sites/default/files/files/Loss%20of%20sense%20of%20smell%20as%20marker%20of%20COVID.pdf
  • 25 Galván Casas C, Català A, Carretero Hernández G. , et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020 ; Doi: 10.1111/bjd.19163
    PubMedGoogle Scholar
  • 26 Jotz GP, Voegels RL, Bento RF. Otorhinolaryngologists and Coronavirus Disease 2019 (COVID-19). Int Arch Otorhinolaryngol 2020; 24 (02) e125 –e128
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 27 Kulcsar MA, Montenegro FL, Arap SS, Tavares MR, Kowalski LP. High Risk of COVID-19 Infection for Head and Neck Surgeons. Int Arch Otorhinolaryngol 2020; 24 (02) e129 –e130
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 28 Lei S, Jiang F, Su W. , et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine 2020; 21: 100331 Doi: 10.1016/j.eclinm.2020.100331
    CrossrefPubMedGoogle Scholar
  • 29 Baig AM, Khan NA. Novel chemotherapeutic strategies in the management of primary amoebic meningoencephalitis due to Naegleria fowleri. CNS Neurosci Ther 2014; 20 (03) 289-290
    CrossrefPubMedGoogle Scholar
  • 30 Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol 2008; 82 (15) 7264-7275 Doi: 10.1128/JVI.00737-08
    CrossrefPubMedGoogle Scholar
  • 31 Baig AM. Neurological manifestations in COVID-19 caused by SARS-CoV-2. CNS Neurosci Ther 2020; 26 (05) 499-501 Doi: 10.1111/cns.13372
    CrossrefPubMedGoogle Scholar
  • 32 Vukkadala N, Qian ZJ, Holsinger FC, Patel ZM, Rosenthal E. . COVID-19 and the otolaryngologist – preliminary evidence-based review. 2020 Mar 26. Doi: 10.1002/lary.28672. Epub ahead of print.
    PubMed
  • 33 Adams JG, Walls RM. Supporting the Health Care Workforce During the COVID-19 Global Epidemic. JAMA 2020 ; Epub ahead of print Doi: 10.1001/jama.2020.3972
    PubMedGoogle Scholar
  • 34 Thanh Le T, Andreadakis Z, Kumar A. , et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020; 19 (05) 305-306 Doi: 10.1038/d41573-020-00073-5
    CrossrefPubMedGoogle Scholar
  • 35 Joseph T. et al. International Pulmonologist's Consensus on COVID-19. 2nd ed. Published on 22nd April 2020 .
    PubMed
  • 36 Wang LF, Lin YS, Huang NC. , et al. Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. J Interferon Cytokine Res 2015; 35 (03) 143-156 Doi: 10.1089/jir.2014.0038
    CrossrefPubMedGoogle Scholar
  • 37 Borges MC, Castro LA, Fonseca BA. Chloroquine use improves dengue-related symptoms. Mem Inst Oswaldo Cruz 2013; 108 (05) 596-599 Doi: 10.1590/S0074-02762013000500010
    CrossrefPubMedGoogle Scholar
  • 38 Paton NI, Lee L, Xu Y. , et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis 2011; 11 (09) 677-683 Doi: 10.1016/S1473-3099(11)70065-2
    CrossrefPubMedGoogle Scholar
  • 39 Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases?. Lancet Infect Dis 2003; 3 (11) 722-727 Doi: 10.1016/S1473-3099(03)00806-5
    CrossrefPubMedGoogle Scholar
  • 40 Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020; 55 (04) 105932 Doi: 10.1016/j.ijantimicag.2020.105932
    CrossrefPubMedGoogle Scholar
  • 41 National Health Commission and State Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia. Accessed March 18, 2020. https://www.chinalawtranslate.com/wp-content/uploads/2020/03/Who-translation.pdf
  • 42 Hydroxychloroquine [database online]. Hudson, OH: Lexicomp Inc; 2016 . Accessed March 17, 2020. http://online.lexi.com
    PubMed
  • 43 Yao X, Ye F, Zhang M. , et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; ciaa237 Doi: 10.1093/cid/ciaa237
    PubMedGoogle Scholar
  • 44 Cao B, Wang Y, Wen D. , et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020; 382 (19) 1787-1799 Doi: 10.1056/NEJMoa2001282
    CrossrefPubMedGoogle Scholar
  • 45 Lopinavir/ritonavir [database online]. Hudson (OH): Lexicomp Inc; 2016 . [cited 2020 March 17]. Available from: http://online.lexi.com
    PubMed
  • 46 Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med 2006; 3 (09) e343 Doi: 10.1371/journal.pmed.0030343
    CrossrefPubMedGoogle Scholar
  • 47 Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020; 14 (01) 58-60 Doi: 10.5582/ddt.2020.01012
    CrossrefPubMedGoogle Scholar
  • 48 Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol 2020; 92 (06) 556-563 Doi: 10.1002/jmv.25729
    CrossrefPubMedGoogle Scholar
  • 49 Chan KS, Lai ST, Chu CM. , et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 2003; 9 (06) 399-406
    PubMedGoogle Scholar
  • 50 Foolad F, Aitken SL, Shigle TL. , et al. Oral versus aerosolized ribavirin for the treatment of respiratory syncytial virus infections in hematopoietic cell transplant recipients. Clin Infect Dis 2019; 68 (10) 1641-1649 Doi: 10.1093/cid/ciy760
    CrossrefPubMedGoogle Scholar
  • 51 ClinicalTrials.gov. [Internet]. [cited 2020 March 18]. Available from: https://clinicaltrials.gov
  • 52 Morra ME, Van Thanh L, Kamel MG. , et al. Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta-analysis. Rev Med Virol 2018; 28 (03) e1977 Doi: 10.1002/rmv.1977
    CrossrefPubMedGoogle Scholar
  • 53 Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020; 19 (03) 149-150 Doi: 10.1038/d41573-020-00016-0
    CrossrefPubMedGoogle Scholar
  • 54 Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion. J Virol 2016; 90 (19) 8924-8933 Doi: 10.1128/JVI.01429-16
    CrossrefPubMedGoogle Scholar
  • 55 Dyall J, Gross R, Kindrachuk J. , et al. Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies. Drugs 2017; 77 (18) 1935-1966 Doi: 10.1007/s40265-017-0830-1
    CrossrefPubMedGoogle Scholar
  • 56 Pfefferle S, Schöpf J, Kögl M. , et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog 2011; 7 (10) e1002331 Doi: 10.1371/journal.ppat.1002331
    CrossrefPubMedGoogle Scholar
  • 57 de Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y. , et al. Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol 2011; 92 (Pt 11): 2542-2548 Doi: 10.1099/vir.0.034983-0
    CrossrefPubMedGoogle Scholar
  • 58 Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020 ; Epub ahead of print Doi: 10.1001/jama.2020.6019
    PubMedGoogle Scholar
  • 59 Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ 2020; 369: m1432 Doi: 10.1136/bmj.m1432
    CrossrefPubMedGoogle Scholar
  • 60 Zhou F. , et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. www.thelancet.com https://doi.org/10.1016/S0140-6736(20)30566-3 . Published online March 9, 2020.
    CrossrefPubMed
  • 61 WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 [Internet]. [cited 2020 Mar 24]. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19–11-march-2020
    PubMed
  • 62 Guan WJ, Ni ZY, Hu Y. , et al; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382 (18) 1708-1720 Doi: 10.1056/NEJMoa2002032
    CrossrefPubMedGoogle Scholar
  • 63 Kock RA, Karesh WB, Veas F. , et al. 2019-nCoV in context: lessons learned?. Lancet Planet Health 2020; 4 (03) e87-e88 Doi: 10.1016/S2542-5196(20)30035-8
    CrossrefPubMedGoogle Scholar
  • 64 Horton R. Offline: A global health crisis? No, something far worse. Lancet 2020; 395 (10234): 1410 Doi: 10.1016/S0140-6736(20)31017-5
    CrossrefPubMedGoogle Scholar
  • 65 Haines A, Ebi K. The Imperative for Climate Action to Protect Health. N Engl J Med 2019; 380 (03) 263-273 Doi: 10.1056/NEJMra1807873
    CrossrefPubMedGoogle Scholar
  • 66 Haines A, Scheelbeek P. European Green Deal: a major opportunity for health improvement. Lancet 2020; 395 (10233): 1327-1329 Doi: 10.1016/S0140-6736(20)30109-4
    CrossrefPubMedGoogle Scholar
  • 67 Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S. COVID-19 Autopsies, Oklahoma, USA. Am J Clin Pathol 2020; 153 (06) 725-733 Doi: 10.1093/ajcp/aqaa062
    CrossrefPubMedGoogle Scholar
  • 68 Carsana, et al. Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy. medRxiv preprint Doi: 10.1101/2020.04.19.20054262 this version posted April 22, 2020
    PubMedGoogle Scholar